U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H32O6
Molecular Weight 404.4975
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROCORTISONE ACETATE

SMILES

CC(=O)OCC(=O)[C@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@]([H])(C[C@@]21C)O)O

InChI

InChIKey=ALEXXDVDDISNDU-JZYPGELDSA-N
InChI=1S/C23H32O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-18,20,26,28H,4-9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1

HIDE SMILES / InChI
Molecular Formula C23H32O6
Molecular Weight 404.4975
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008697s032_33lbl.pdf

Hydrocortisone is the main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). Hydrocortisone is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.

CNS Activity

CNS Penetrant
2415
Curator's Comment:: shown in dogs

Originator

Approval Year

1951
105
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2456
Congenital adrenal hyperplasia
Rheumatoid arthritis
Leukemia
Bronchial asthma
Agonist
2456
Agonist
2456
Inhibitor
7701
 50 nM [IC50]
Annexin A1
17
Target ID: P04083
Gene ID: 301
Gene Symbol: ANXA1
Target Organism: Homo sapiens (Human)
Agonist
2456
Inhibitor
7701
Bronchial asthma
 0.100000000000000006 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Glucocorticoid receptor
Approved
7997
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-538012800000
Primary
Glucocorticoid receptor
Approved
7997
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-538012800000
Palliative
Glucocorticoid receptor
Approved
7997
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-538012800000
Primary
Intercellular adhesion molecule-1
Glucocorticoid receptor
Approved
7997
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-538012800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
258 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2050835
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1162 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2050835
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.82 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2050835
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
9.9%
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/13700365
HYDROCORTISONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 4 times / day multiple, intramuscular
Highest studied dose
Dose: 200 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32170323
unhealthy, 56 years (tange: 40-64 years)
Health Status: unhealthy
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32170323
Sources:
https://pubmed.ncbi.nlm.nih.gov/32170323
200 mg 4 times / day multiple, intravenous
Highest studied dose
Dose: 200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32170323
unhealthy, 56 years (tange: 40-64 years)
Health Status: unhealthy
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32170323
Sources:
https://pubmed.ncbi.nlm.nih.gov/32170323
200 mg 4 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 4 times / day
Route: oral
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32170323
unhealthy, 56 years (tange: 40-64 years)
Health Status: unhealthy
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32170323
Sources:
https://pubmed.ncbi.nlm.nih.gov/32170323
200 mg single, intravenous
Highest studied dose
Dose: 200 mg
Route: intravenous
Route: single
Dose: 200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/32170323
unhealthy, 56 years (tange: 40-64 years)
Health Status: unhealthy
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32170323
Sources:
https://pubmed.ncbi.nlm.nih.gov/32170323
2.5 % 4 times / day multiple, topical
Dose: 2.5 %, 4 times / day
Route: topical
Route: multiple
Dose: 2.5 %, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/40310_Hydrocortisone_Prntlbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/40310_Hydrocortisone_Prntlbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/40310_Hydrocortisone_Prntlbl.pdf
1 mg/kg 4 times / day multiple, intravenous
Dose: 1 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 4 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02044159
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT02044159
Other AEs: Infection...
Other AEs:
Infection (below serious, 6 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT02044159
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01954056
unhealthy, neonate
Health Status: unhealthy
Age Group: neonate
Sources:
https://clinicaltrials.gov/ct2/show/NCT01954056
Other AEs: Hyperbilirubinemia, Hypertension...
Other AEs:
Hyperbilirubinemia (serious, 1 patient)
Hypertension (serious, 1 patient)
Adrenal insufficiency (serious, 1 patient)
Sources:
https://clinicaltrials.gov/ct2/show/NCT01954056
AEs

AEs

AESignificanceDosePopulation
Infection below serious, 6 patients
1 mg/kg 4 times / day multiple, intravenous
Dose: 1 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 4 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02044159
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT02044159
Adrenal insufficiency serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01954056
unhealthy, neonate
Health Status: unhealthy
Age Group: neonate
Sources:
https://clinicaltrials.gov/ct2/show/NCT01954056
Hyperbilirubinemia serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01954056
unhealthy, neonate
Health Status: unhealthy
Age Group: neonate
Sources:
https://clinicaltrials.gov/ct2/show/NCT01954056
Hypertension serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01954056
unhealthy, neonate
Health Status: unhealthy
Age Group: neonate
Sources:
https://clinicaltrials.gov/ct2/show/NCT01954056
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inducer
657
inducer
22

OverviewOther

Other InhibitorOther SubstrateOther Inducer
11-beta-HSD2
27
MRP2
100

MRP3
55
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
MRP2
421
 no
CYP3A4
1462
 yes [EC50 0.6 uM]
Kv1.3
31
 yes [IC50 33.4 uM]
Kv1.5
40
 yes [IC50 33.4 uM]
GLUT4
17
 yes
MRP3
200
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
11-beta-HSD2
27
 major
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1392
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P003ARM
A2B Chem
AB53122
AK Scientific
C481
AK Scientific
J10114
AK Scientific
J92891
APExBIO
B1951
AbovChem LLC
HY-N0583
Acros Organics
35245
Alfa Chemistry
A16292
Alinda
ALBB-025803
Alinda
IBS-E0731050
Angene
AGN-PC-0WH3U2
AstaTech
42245
BOC Sciences
50-23-7
Bide Pharmatech
BD134115
BioSynth
Q-201211
Bosche Scientific
H2132
Cayman Chemical
20739
Chem Scene
CS-2226
Chem4Pharma
C4PST426
ChemDiv
BB57-6734
ChemDiv
N046-0008
ChemShuttle
151488
Combi-Blocks
QA-0828
Compound Cloud
5754
Enamine
EN300-120630
Enamine
Z2786051549
Fluorochem
358100
Hangzhou APIChem Technology
AC-12902
Hangzhou Yuhao Chemical Technology
LT1240
IBScreen
BB_NC-00611
IBScreen
Bio-0648
KeyOrganics
AS-11651
Lab Network
LN00830918
Lab Seeker
SC-18577
MedChem Express
HY-N0583
MolPort
MolPort-001-794-637
Molnova
M14696
NCI Plated 2007
10483
NCI Plated 2007
23903
NCI Plated 2007
27390
Pharmeks
PHBB_NC-02501
Ryan Scientific
074-61028
Ryan Scientific
Minocycline_HCl
Selleck Chemicals
S1696
ShangHai Biochempartner
BCP09054
Sigma Aldrich
1316004
Sigma Aldrich
1316004|USP
Sigma Aldrich
286095
Sigma Aldrich
286095|ALDRICH
Sigma Aldrich
31719
Sigma Aldrich
31719|SIAL
Sigma Aldrich
BP576
Sigma Aldrich
C-106
Sigma Aldrich
C-106|CERILLIAN
Sigma Aldrich
H0135
Sigma Aldrich
H0135|SIGMA
Sigma Aldrich
H0396
Sigma Aldrich
H0396|SIGMA
Sigma Aldrich
H0888
Sigma Aldrich
H0888|SIGMA
Sigma Aldrich
H1300000
Sigma Aldrich
H1300000|SIAL
Sigma Aldrich
H3160
Sigma Aldrich
H3160|SIGMA
Sigma Aldrich
H4001
Sigma Aldrich
H4001|SIGMA
Sigma Aldrich
H6909
Sigma Aldrich
H6909|SIGMA
Sigma Aldrich
PHR1014
Sigma Aldrich
PHR1014|SIAL
Sigma Aldrich
Y0001092
Sigma Aldrich
Y0001092|SIAL
StruChem
SC-18577
TargetMol
50-23-7
TargetMol
HMDB0000063
TargetMol
T1614
Tetrahedron
TS79645
TimTec
SBB012589
TimTec
ST069286
Tocris
4093
Toronto Research Chemicals
H714615
W&J PharmaChem
100374
ZINC
ZINC000013540519
http://zinc15.docking.org/substances/ZINC000013540519
mcule
MCULE-8463642691
mcule
MCULE-8953627920
PubMed

PubMed

TitleDatePubMed
Complications of lumbar puncture with injection of hydrosoluble material.
1999 Apr
Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids.
1999 Apr
The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers.
1999 Aug
New weakness in a critically ill patient.
1999 Dec
Delayed generalized allergic reactions to corticosteroids.
2000
[Respiratory muscle weakness after prolonged use of hydrocortisone and pancuronium bromide].
2000 Jan
Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding.
2000 Jun 23
Role of erythropoietin in cortisol-induced hypertension.
2000 Mar
Functional adrenocorticotropic hormone receptor in cultured human vascular endothelial cells : possible role in control of blood pressure.
2000 Nov
Inducers of gamma-glutamylcysteine synthetase and their effects on glutathione synthetase expression.
2000 Sep 7
Endocrine and metabolic effects of insulin sensitizers in the treatment of patients with polycystic ovary syndrome and hyperinsulinaemia.
2001
Effect of ruminations on the saliva cortisol response to a social stressor.
2001 Apr
Enhanced memory for emotional material following stress-level cortisol treatment in humans.
2001 Apr
Gender differences in age-related changes in HPA axis reactivity.
2001 Apr
Regulation of interleukin 1 beta RNA expression in the common carp, Cyprinus carpio L.
2001 Apr
Circulatory support of the sick preterm infant.
2001 Feb
Modulation of P450 CYP3A4-dependent metabolism by P-glycoprotein: implications for P450 phenotyping.
2001 Feb
Regulation of phosphate uptake in primary cultured rabbit renal proximal tubule cells by glucocorticoids: evidence for nongenomic as well as genomic mechanisms.
2001 Feb
Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome.
2001 Feb
The effects of epidural block on the distribution of lymphocyte subsets and natural-killer cell activity in patients with and without pain.
2001 Feb
Pulsatile growth hormone secretion decreases S-adenosylmethionine synthetase in rat liver.
2001 Feb
Urinary thromboxane, prostacyclin, cortisol, and 8-hydroxy-2'-deoxyguanosine in nonsmokers exposed and not exposed to environmental tobacco smoke.
2001 Feb
Cooperative effects of STAT5 (signal transducer and activator of transcription 5) and C/EBPbeta (CCAAT/enhancer-binding protein-beta) on beta-casein gene transcription are mediated by the glucocorticoid receptor.
2001 Feb
Cord blood leptin and insulin-like growth factor levels are independent predictors of fetal growth.
2001 Feb
Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade.
2001 Feb
The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis.
2001 Feb
Troglitazone amplifies counterregulatory responses to hypoglycemia in nondiabetic subjects.
2001 Feb
Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.
2001 Feb
Fertility and body composition after laparoscopic bilateral adrenalectomy in a 30-year-old female with congenital adrenal hyperplasia.
2001 Feb
Electrophysiological effects of corticosteroids on the retinal pigment epithelium.
2001 Feb
Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
2001 Feb
Dose response of arginine vasopressin to the CCK-B agonist pentagastrin.
2001 Feb
Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results.
2001 Feb
Green fluorescent protein mutant as label in homogeneous assays for biomolecules.
2001 Feb 1
Post-dexamethasone cortisol level and memory performance in elderly depressed patients.
2001 Feb 2
Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via alpha-hydroxylation and carbonyl reduction pathways.
2001 Jan
Tixocortol pivalate contact allergy in the GPMT: frequency and cross-reactivity.
2001 Jan
Serum allopregnanolone in women with postpartum "blues".
2001 Jan
Back to basics: early diagnosis and compliance improve final height outcome in congenital adrenal hyperplasia.
2001 Jan
Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans.
2001 Jan
Reference intervals for glucose, beta-cell polypeptides, and counterregulatory factors during prolonged fasting.
2001 Jan
Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus.
2001 Jan
Hydrocortisone abolishes the angiotensin II-mediated potentiation of endothelin-1 in bovine bronchi.
2001 Jan
Lower baseline plasma cortisol and prolactin together with increased body temperature and higher mCPP-induced cortisol responses in men with pedophilia.
2001 Jan
Neuroendocrine responses to experimentally-induced psychological stress in healthy humans.
2001 Jan
A population physiologically based pharmacokinetic/pharmacodynamic model for the inhibition of 11-beta-hydroxysteroid dehydrogenase activity by glycyrrhetic acid.
2001 Jan 1
Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes.
2001 Jan 1
Neural correlates of maternal separation in rhesus monkeys.
2001 Jan 15
Altered levels of hypothalamic-pituitary-adrenocortical axis hormones in baboons and mice during the course of infection with Schistosoma mansoni.
2001 Jan 15
Fetal hypothalamus-pituitary-adrenal axis on the road to parturition.
2001 Jan-Feb
Patents

Patents

04221787
15
05089423
15
05616573
15
06713507
15
JP2000275248A
15
JP2002333448A
15
JP2002511777A
382
JP2002544210A
86
JP2005521637A
16
JP2006516338A
15
JP2006517850A
53
JP2006520379A
67
JP2007015930A
15
JP2007024822A
15
JP2007077146A
15
JP2007537998A
15
JP2008178419A
15
JP2009051858A
18
JP2009102343A
15
JP2010506837A
73
JP4790123B2
46
JP4812169B2
18
JPH01158963A
15
JPH01190628A
15
JPH02113885A
15
JPH02178228A
15
JPH03109332A
17
JPH04234804A
15
JPH04308530A
35
JPH05139954A
15
JPH054924A
37
JPH11190736A
15
JPH1123579A
15
JPS05564600A
15
JPS56147799A
15
JPS58225010A
15
JPS5988428A
15
JPS62174008A
15
JPS63267722A
15
JPS6471899A
15

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Many Hydrocortisone products are used topically https://www.drugs.com/pro/hydrocortisone.html
The initial dosage of CORTEF (Hydrocortisone) Tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated.
Route of Administration: Oral
In Vitro Use Guide
Hydrocortisone concentration-dependently inhibited the current induced by 3 x 10(-5) M ACh with a half maximum inhibitory concentration (IC50) of 2.1 x 10(-4) M (in rats).
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:46:39 UTC 2021
Edited
by admin
on Fri Jun 25 20:46:39 UTC 2021
Record UNII
3X7931PO74
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROCORTISONE ACETATE
EP   GREEN BOOK   INCI   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INCI  
Official Name English
HYDROCORTISONE HYDROGEN SUCCINATE IMPURITY B [EP]
Common Name English
HYDROCORTISONE ACETATE COMPONENT OF TERRA-CORTRIL
Common Name English
DRICORT
Brand Name English
HYDROCORTISONE ACETATE [ORANGE BOOK]
Common Name English
HYDROCORTISONE ACETATE COMPONENT OF CARMOL HC
Common Name English
HYDROCORTISONE SODIUM SUCCINATE IMPURITY B [EP]
Common Name English
HYDROCORTISONE ACETATE COMPONENT OF NEO-CORTEF
Common Name English
HYDROCORTISONI ACETAS [WHO-IP LATIN]
Common Name English
HYDROCORTISONE ACETATE [EP]
Common Name English
HYDROCORTISONE ACETATE COMPONENT OF U-CORT
Common Name English
HYDROCORTISONE ACETATE [WHO-DD]
Common Name English
PREDNISOLONE ACETATE IMPURITY A [EP]
Common Name English
EPIFOAM COMPONENT HYDROCORTISONE ACETATE
Common Name English
HYDROCORTISONE ACETATE [MART.]
Common Name English
TERRA-CORTRIL COMPONENT HYDROCORTISONE ACETATE
Common Name English
PRAMOSONE COMPONENT HYDROCORTISONE ACETATE
Common Name English
HYDROCORTISONE ACETATE [USP-RS]
Common Name English
HYDROCORTISONE ACETATE COMPONENT OF PRAMOSONE
Common Name English
HEMSOL-HC
Brand Name English
HYDROCORTISONE ACETATE [USP MONOGRAPH]
Common Name English
CARMOL HC COMPONENT HYDROCORTISONE ACETATE
Common Name English
COR-OTICIN COMPONENT HYDROCORTISONE ACETATE
Common Name English
HYDROCORTISONE ACETATE [INCI]
Common Name English
HYDROCORTISONE ACETATE COMPONENT OF COR-OTICIN
Common Name English
HYDROCORTISONE ACETATE COMPONENT OF EPIFOAM
Common Name English
HYDROCORTISONE 21-ACETATE
MI  
Common Name English
ORABASE HCA
Brand Name English
HYDROCORTISONE ACETATE COMPONENT OF CHLOROMYCETIN HYDROCORTISONE
Common Name English
HYDROCORTISONE ACETATE COMPONENT OF PROCTOFOAM HC
Common Name English
NSC-741
Code English
CORTIFOAM
Brand Name English
NEO-CORTEF COMPONENT HYDROCORTISONE ACETATE
Common Name English
COLY-MYCIN S COMPONENT HYDROCORTISONE ACETATE
Common Name English
HYDROCORTISONE IMPURITY C [EP]
Common Name English
HYDROCORTISONE ACETATE [GREEN BOOK]
Common Name English
MICORT-HC
Brand Name English
PREGN-4-ENE-3,20-DIONE, 21-(ACETYLOXY)-11,17-DIHYDROXY-, (11.BETA.)-
Systematic Name English
CHLOROMYCETIN HYDROCORTISONE COMPONENT HYDROCORTISONE ACETATE
Common Name English
HYDROCORTISONE ACETATE [WHO-IP]
Common Name English
OPHTHOCORT COMPONENT HYDROCORTISONE ACETATE
Common Name English
HYDROCORTISONE ACETATE [VANDF]
Common Name English
HYDROCORTISONE ACETATE COMPONENT OF COLY-MYCIN S
Common Name English
HYDROCORTISONE 21-ACETATE [MI]
Common Name English
U-CORT COMPONENT HYDROCORTISONE ACETATE
Common Name English
PROCTOFOAM HC COMPONENT HYDROCORTISONE ACETATE
Common Name English
HYDROCORTISONE ACETATE COMPONENT OF OPHTHOCORT
Common Name English
CORTEF ACETATE
Brand Name English
HYDROCORTISONE ACETATE [EP MONOGRAPH]
Common Name English
CORTISOL 21-ACETATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
FDA ORPHAN DRUG 568616
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
Code System Code Type Description
DRUG CENTRAL
4213
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY
RXCUI
27197
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY RxNorm
CAS
50-03-3
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY
MESH
C021650
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY
EVMPD
SUB02562MIG
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
HYDROCORTISONE ACETATE
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Practically insoluble in water; slightly soluble in ethanol (~750 g/l) TS; very slightly soluble in ether R. Category: Adrenocortical steroid. Storage: Hydrocortisone acetate should be kept in a well-closed container, protected from light.Additional information: Hydrocortisone acetate melts at about 220?C with decomposition. Definition: Hydrocortisone acetate contains not less than 97.0% and not more than 102.0% of C23H32O6, calculated with reference to the dried substance.
ECHA (EC/EINECS)
200-004-4
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY
DRUG BANK
DB14539
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY
NCI_THESAURUS
C61785
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY
MERCK INDEX
M6094
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY Merck Index
FDA UNII
3X7931PO74
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY
ChEMBL
CHEMBL1091
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY
EPA CompTox
50-03-3
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY
PUBCHEM
5744
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY
USP_CATALOG
1317007
Created by admin on Fri Jun 25 20:46:39 UTC 2021 , Edited by admin on Fri Jun 25 20:46:39 UTC 2021
PRIMARY USP-RS
Related Record Type Details
Structure of PREDNISOLONE ACETATE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CORTISONE ACETATE
IMPURITY -> PARENT
Structure of HYDROCORTISONE SODIUM SUCCINATE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ANECORTAVE ACETATE
IMPURITY -> PARENT
Structure of EPI-HYDROCORTISONE ACETATE
IMPURITY -> PARENT
Structure of HYDROCORTISONE HEMISUCCINATE ANHYDROUS
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of HYDROCORTISONE ACETATE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CORTISONE ACETATE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of HYDROCORTISONE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of HYDROCORTISONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966